• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 11th January 2016

Seminar at Glasgow Caledonian University: Local Health Care Expenditure Plans and Their Opportunity Costs

OHE’s Sarah Karlsberg Schaffer presented at the Glasgow Health Economics Seminar Series the results of a paper on the value of the cost-effectiveness threshold in Scotland. In November, OHE’s Sarah Karlsberg Schaffer presented at the Glasgow health Economics Seminar Series…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
Glasgow-small

OHE’s Sarah Karlsberg Schaffer presented at the Glasgow Health Economics Seminar Series the results of a paper on the value of the cost-effectiveness threshold in Scotland.

In November, OHE’s Sarah Karlsberg Schaffer presented at the Glasgow health Economics Seminar Series (GhESS) the results of a paper on the value of the cost per quality-adjusted life year (QALY) threshold in Scotland.

The paper, written with Jon Sussex, Nancy Devlin and Andrew Walker, and recently published in Health Policy, tests the feasibility of estimating the “true” cost per QALY threshold using information on the cost-effectiveness of “marginal” services in NHS Scotland – those planned to receive significant investment or disinvestment in the coming financial year. It also explores how the NHS makes spending decisions and the role of cost per QALY evidence in this process.

The first key finding presented by Sarah was that the cost-effectiveness of marginal services varies hugely, as is evident from Figure 1 (below). For this reason, the authors were not able to obtain a reliable estimate of the cost per QALY threshold.

This result is unsurprising given the second key finding: cost-effectiveness evidence was very rarely used to justify expenditure plans, which were driven by a range of other factors including Scottish Government initiatives, patient convenience, political pressure and centrally-led waiting time targets.

Figure 1: Cost per QALY of marginal services in NHS Scotland 2012/13

OVS = Orthoptic vision screening; PET = Positron emission tomography; AAA = Abdominal aortic aneurysm screening; PBT: Proton beam therapy; CPAP = Continuous positive airway pressure; ABI = Alcohol brief interventions

These results highlight the differences in objectives between HTA bodies (which make their recommendation decisions primarily on the basis of cost per QALY evidence) and local health service decision-makers. This has important implications for the interpretation of the threshold: if the NHS does not make spending decisions based on cost per QALY evidence, then a cost-effectiveness threshold expressed in QALYs is unlikely to represent the true opportunity cost of HTA decisions.

Finally, Sarah highlighted the difficulty experienced by the authors in attempting to locate evidence on the cost-effectiveness of various NHS services. She argued, therefore, that even if it were desirable, the use of cost-effectiveness evidence at local level would be highly challenging without extensive investment in health economics resources.

Sarah’s slides are available below:

Local health care expenditure plans and their opportunity costs from Office of Health Economics
  • Health Technology Assessment…
  • Value, Affordability, and…
  • NICE

Related News

  • News
  • September 2020

Assessing the Productivity Value of Vaccines in Health Technology Assessment: Worth a Shot?

Read more
  • News
  • August 2020

Are Discount Rates Used in UK Vaccine Economic Evaluations Jeopardising Investment in Immunisation Programmes?

Read more
  • News
  • July 2020

NICE ‘Optimised’ Recommendations: What Do They Mean for Patient Access?

Read more
  • News
  • March 2020

How do we Get and Pay for New Antibiotics? Proposed New Models for Value Assessment and Contracting for Payment.

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!